Quadrature Capital Ltd Trims Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Quadrature Capital Ltd lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) by 59.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 13,941 shares of the company’s stock after selling 20,669 shares during the quarter. Quadrature Capital Ltd’s holdings in Medpace were worth $4,273,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Medpace by 2.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock worth $2,114,000 after buying an additional 148 shares during the period. Portside Wealth Group LLC grew its holdings in Medpace by 14.8% during the 4th quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock worth $435,000 after acquiring an additional 183 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Medpace by 355.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock worth $1,090,000 after acquiring an additional 2,774 shares in the last quarter. Norden Group LLC boosted its holdings in shares of Medpace by 207.8% in the 4th quarter. Norden Group LLC now owns 5,014 shares of the company’s stock valued at $1,537,000 after buying an additional 3,385 shares in the last quarter. Finally, Evoke Wealth LLC bought a new stake in shares of Medpace in the 4th quarter valued at about $3,149,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 5,695 shares of Medpace stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $395.49, for a total transaction of $2,252,315.55. Following the completion of the transaction, the chief executive officer now directly owns 654,656 shares of the company’s stock, valued at approximately $258,909,901.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO August J. Troendle sold 3,987 shares of Medpace stock in a transaction on Friday, May 24th. The shares were sold at an average price of $395.22, for a total value of $1,575,742.14. Following the sale, the chief executive officer now owns 660,351 shares of the company’s stock, valued at approximately $260,983,922.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO August J. Troendle sold 5,695 shares of Medpace stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $395.49, for a total transaction of $2,252,315.55. Following the completion of the sale, the chief executive officer now directly owns 654,656 shares in the company, valued at approximately $258,909,901.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,973 shares of company stock valued at $11,960,425. 20.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MEDP. Mizuho began coverage on shares of Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price target on the stock. Guggenheim raised their price target on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target on the stock. Robert W. Baird lifted their target price on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $443.14.

Check Out Our Latest Stock Report on Medpace

Medpace Price Performance

MEDP traded down $1.90 during trading on Friday, reaching $401.19. 115,367 shares of the company’s stock were exchanged, compared to its average volume of 161,081. Medpace Holdings, Inc. has a 1 year low of $207.47 and a 1 year high of $421.00. The stock has a market capitalization of $12.43 billion, a P/E ratio of 40.90, a price-to-earnings-growth ratio of 1.99 and a beta of 1.39. The company’s fifty day simple moving average is $393.68 and its 200-day simple moving average is $353.75.

Medpace (NASDAQ:MEDPGet Free Report) last posted its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same period last year, the firm posted $2.27 EPS. Medpace’s revenue for the quarter was up 17.7% compared to the same quarter last year. Equities analysts forecast that Medpace Holdings, Inc. will post 11.29 EPS for the current year.

Medpace Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Further Reading

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPFree Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.